New treatments to fight antibiotic-resistant Pseudomonas aeruginosa infections
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa
This study is looking for new ways to treat tough infections caused by a super-resistant bacteria called Pseudomonas aeruginosa, so that patients can have better options and outcomes when dealing with these hard-to-treat infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11081794 on NIH RePORTER |
What this research studies
This research focuses on developing innovative combination therapies to address infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA), which are increasingly difficult to treat due to their high-level resistance. The study aims to explore the mechanisms behind hypermutable strains of this bacteria, which can adapt and survive treatment. By investigating non-traditional pathways and utilizing novel non-natural nucleotides, the research seeks to create effective treatment regimens that can overcome the challenges posed by these resistant strains. Patients may benefit from new therapeutic options that could improve outcomes in severe infections.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with infections caused by carbapenem-resistant Pseudomonas aeruginosa.
Not a fit: Patients with infections caused by bacteria that are not resistant to carbapenems may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from difficult-to-treat bacterial infections.
How similar studies have performed: While the approach of targeting hypermutable strains is innovative, there is emerging evidence suggesting that similar strategies have shown promise in other antibiotic resistance research.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Tsuji, Brian — State University of New York at Buffalo
- Study coordinator: Tsuji, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.